...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Laryngoscope: A Medical Journal for Clinical and Research Contributions in Otolaryngology, Head and Neck Medicine and Surgery, Facial Plastic and Reconstructive Surgery .. >Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: A Systematic Review
【24h】

Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: A Systematic Review

机译：皮下免疫疗法治疗变应性鼻结膜炎和哮喘的有效性：系统评价

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives/Hypothesis To systematically review the effectiveness and safety of subcutaneous immunotherapy (SCIT) for treatment of allergic rhinoconjunctivitis and asthma, using formulations currently approved in the United States. Study Design We searched the following databases up to May 21, 2012: MEDLINE, Embase, LILACS, and the Cochrane Central Register of Controlled Trials. Methods We included randomized controlled trials published in English comparing SCIT to placebo, pharmacotherapy, or other SCIT regimens that reported clinical outcomes of interest. Studies of adults or mixed age populations were included. Studies were excluded if the diagnosis of allergy and/or asthma was not confirmed with objective testing. Paired reviewers selected articles for inclusion and extracted data. We assessed the risk of bias for each study and graded the strength of evidence for each outcome as high, moderate, or low. Results Sixty-one studies met our inclusion criteria. Majority of the studies (66%) evaluated single-allergen immunotherapy regimens. The literature provides high-grade evidence that SCIT reduces asthma symptoms, asthma medication usage, rhinitis/rhinoconjunctivitis symptoms, conjunctivitis symptoms, and rhinitis/rhinoconjunctivitis disease-specific quality of life in comparison to placebo or usual care. There is moderate evidence that SCIT decreases rhinitis/rhinoconjunctivitis medication usage. Respiratory reactions were the most common systemic reaction. There were few reports of anaphylaxis; no deaths were reported. Conclusions Generally moderate to strong evidence supports the effectiveness of SCIT for treatment of allergic rhinitis and asthma, particularly with single-allergen immunotherapy regimens. Adverse reactions to SCIT are common, but no deaths were reported in the included studies.
机译：目的/假设使用目前在美国获得批准的制剂，系统地回顾皮下免疫疗法（SCIT）在治疗变应性鼻结膜炎和哮喘中的有效性和安全性。研究设计我们搜索了截至2012年5月21日的以下数据库：MEDLINE，Embase，LILACS和Cochrane对照试验中央注册簿。方法我们纳入了以英语发表的随机对照试验，将SCIT与安慰剂，药物治疗或其他SCIT方案进行了比较，这些方案报告了感兴趣的临床结局。包括成年人或混合年龄人群的研究。如果未通过客观测试确认过敏和/或哮喘的诊断，则排除研究。配对的审阅者选择了要纳入和提取数据的文章。我们评估了每项研究的偏倚风险，并将每种结果的证据强度分为高，中或低。结果61项研究符合我们的纳入标准。大多数研究（66％）评估了单一过敏原免疫治疗方案。文献提供了高级证据，与安慰剂或常规护理相比，SCIT减少了哮喘症状，哮喘药物的使用，鼻炎/鼻结膜炎症状，结膜炎症状以及鼻炎/鼻结膜炎疾病特定的生活质量。有中度证据表明SCIT减少了鼻炎/鼻结膜炎的药物使用量。呼吸系统反应是最常见的全身反应。很少有过敏反应的报道。没有死亡的报道。结论一般而言，中到有力的证据支持SCIT治疗变应性鼻炎和哮喘的有效性，尤其是采用单一变应原免疫疗法时。对SCIT的不良反应很普遍，但纳入研究未报告有死亡病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号